Compound class:
Synthetic organic
Comment: This DPP-4 inhibitor as a potential treatment for type 2 diabetes mellitus. ZY15557 is from the Indian company Zydus Research Centre, Cadila Healthcare [2]. The structure corresponds to example 17 in [1]. The patent includes 257 analogues but binned IC50s for only 50.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
ZY15557 has a more sustained action and half-life than sitagliptin for mouse and other species studied in the developer's 2017 paper [2] |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|